Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | MEN1 | O00255 | 8/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.64 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.64 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 9/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.55 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | MITF | O75030 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NOS1 | P29475 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29800698 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL22120229 | 0.81 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL4642926 | 0.78 | MEN1 (0.67) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL317836 | 0.78 | KMT2A (1.00) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL31067265 | 0.78 | ALDH1A1 (0.67) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL6538214 | 0.78 | MAPT (0.77) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL5260391 | 0.77 | PDE10A (0.62) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL6537575 | 0.76 | KDM4E (0.63) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL9364397 | 0.76 | MEN1 (0.63) | ALDH1A1MEN1KMT2ATDP1KDM4E | |
| SCHEMBL7571608 | 0.76 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ATDP1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2015-08-06 | — | — | US | disclosed |
| EP-2892344-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | Bayer CropScience AG (DE) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014037313-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | BAYER CROPSCIENCE AG (DE) | 2014-03-13 | — | — | WO | disclosed |
| EP-0538297-B9 | ANTIVIRAL TETRAHYDROIMIDAZO 1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA NV (BE) | 2002-10-16 | — | — | EP | disclosed |
| EP-0538297-B1 | ANTIVIRAL TETRAHYDROIMIDAZO 1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA NV (BE) | 2001-09-19 | — | — | EP | disclosed |
| US-6201119-B1 | 2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPIN-9-AMINE COMPOUNDS USEFUL AS INTERMEDIATES TO ANTIVIRALS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-03-13 | — | — | US | disclosed |
| US-5371079-A | Administering to inhibit replication of HIV-1 in human cells | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-12-06 | — | — | US | disclosed |
| US-5270464-A | Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-12-14 | — | — | US | disclosed |
| EP-0538297-A1 | ANTIVIRAL TETRAHYDROIMIDAZO 1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-04-28 | — | — | EP | disclosed |
| EP-0384522-B1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1993-01-13 | — | — | EP | disclosed |
| WO-1992000979-A1 | ANTIVIRAL TETRAHYDROIMIDAZO[1,4]BENZODIAZEPIN-2-(THIO)ONES | JANSSEN PHARMACEUTICA N.V. (BE) | 1992-01-23 | — | — | WO | disclosed |
| EP-0384522-A1 | Antiviral tetrahydroimidazo[1,4]benzodiazepin-2-thiones | JANSSEN PHARMACEUTICA N.V. (BE) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218110-A1 | USE OF SUBSTITUTED BENZODIAZEPINONES AND BENZAZEPINONES OR THE SALTS THEREOF AS ACTIVE SUBSTANCES AGAINST ABIOTIC PLANT STRESS | GABBR1, GABRA1, GABRA6 | ALDH1A1 469/4885MEN1 4596/4885KMT2A 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.